Osteoporosis and fracture risk in people with schizophrenia
about
Effects of Antipsychotics on Bone Mineral Density in Patients with Schizophrenia: Gender DifferencesBone Mineral Density in Schizophrenia: An Update of Current Meta-Analysis and Literature Review Under Guideline of PRISMALower Bone Mineral Density at the Hip and Lumbar Spine in People with Psychosis Versus Controls: a Comprehensive Review and Skeletal Site-Specific Meta-analysisChlorpromazine-Induced Hyperprolactinemia on Rat's UterusThe association between major depressive disorder, use of antidepressants and bone mineral density (BMD) in menChronic Psychosocial Stress Impairs Bone Homeostasis: A Study in the Social Isolation Reared Rat.The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review.Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review.Using aripiprazole to reduce antipsychotic-induced hyperprolactinemia: meta-analysis of currently available randomized controlled trialsEffects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder.Bone Mineral Density as a Marker of Cumulative Estrogen Exposure in Psychotic Disorder: A 3 Year Follow-Up StudyProlactin related symptoms during risperidone maintenance treatment: results from a prospective, multicenter study of schizophrenia.Possible factors influencing the duration of hospital stay in patients with psychiatric disorders attempting suicide by jumping.Parameters of Calcium Metabolism Fluctuated during Initiation or Changing of Antipsychotic Drugs.Osteoporosis associated with antipsychotic treatment in schizophreniaDo psychiatric comorbidities influence inpatient death, adverse events, and discharge after lower extremity fractures?The incidence and risk of osteoporosis in patients with anxiety disorder: A Population-based retrospective cohort study.Drug-induced hypo- and hyperprolactinemia: mechanisms, clinical and therapeutic consequences.A meta-analysis of prevalence estimates and moderators of low bone mass in people with schizophrenia.Bone, brain & beyond.Relationship between antipsychotic medication, serum prolactin levels and osteoporosis/osteoporotic fractures in patients with schizophrenia: a critical literature review.A review of the nutritional challenges experienced by people living with severe mental illness: a role for dietitians in addressing physical health gaps.Omega-3 fatty acids supplementation with lithium and aripiprazole for improving the balance of circulating hormones and brain neurotransmitters in manic mice model.Gender-specific risk factors for low bone mineral density in patients taking antipsychotics for psychosis.Is there a nexus between mental and bone health?Frequency of hyperprolactinemia and its associations with demographic and clinical characteristics and antipsychotic medications in psychiatric inpatients in China.The Influence of Psychiatric Comorbidity on Inpatient Outcomes following Distal Humerus Fractures
P2860
Q26739664-172177B0-68C0-4D88-9262-1D1AC1522B6EQ26775158-86C79681-0FF4-4F0B-ABCE-8B6FB3CD6416Q28073179-8F811DC4-D99C-4091-A100-694D2670481EQ28607320-A5539CB3-06DF-44B3-B694-38C7FD81ABA6Q29247902-6B438F58-8A7A-46A1-8B73-359CBBE57DF7Q30380187-34A97DC0-766C-450B-A719-3875B0EB323DQ33619940-EF7CCD8B-A4C3-4918-8DF3-3119EEA5EE81Q33878816-484EDCCA-EBDB-40AB-8CF6-F0940F3CE836Q35214820-623857D2-EA4B-45FD-836C-A6EE9ABD57C1Q35754726-4C89D26C-7870-46A0-9D8A-B1B2F6D25E52Q35756140-38CAFAE7-ED01-4738-A95C-9DCF802A0D9DQ36188000-3D6EEF51-D83A-4351-9C83-83AE25D8DEADQ36315397-9AD98932-F879-4F13-B258-EE890626090EQ36431173-180CC96D-9F17-4C61-9132-FD5ED8A2D327Q36838238-DBEBA377-87C3-4216-9BBB-FE5A999EB6A0Q37170963-2D240689-C4FB-48D7-A9D4-3A3E8D873168Q37300637-8442B612-3B45-4EBC-A825-D25F5AD37013Q38100267-52AD8F68-FE06-4F3D-AD41-5A4698016DCCQ38231654-DDCE3A21-FBA3-4821-A0E9-2A482BB63E75Q38378351-931AB653-2B1D-48DC-83FB-44EBAD8147AFQ38778145-A3E545FB-1B60-451F-BD66-4FB3D6C7D34CQ39248575-3EF79302-5EBF-461C-A912-9C491C3FE9FEQ47242174-B0F7D551-788A-4B15-A0FE-5BF400639917Q47557751-E642AC07-390F-40B3-8806-7DA132F97FEDQ48003490-4F3E66D8-3128-47D5-A755-F179991B4DD0Q48397820-DE8FC7BE-D73D-4F6D-8F97-F097C6A45E04Q59122810-8EBD352B-57E7-4020-B795-8ED86E6966A6
P2860
Osteoporosis and fracture risk in people with schizophrenia
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Osteoporosis and fracture risk in people with schizophrenia
@ast
Osteoporosis and fracture risk in people with schizophrenia
@en
type
label
Osteoporosis and fracture risk in people with schizophrenia
@ast
Osteoporosis and fracture risk in people with schizophrenia
@en
prefLabel
Osteoporosis and fracture risk in people with schizophrenia
@ast
Osteoporosis and fracture risk in people with schizophrenia
@en
P2093
P2860
P1476
Osteoporosis and fracture risk in people with schizophrenia
@en
P2093
Christoph U Correll
Harold E Carlson
Marc De Hert
Peter Manu
Taishiro Kishimoto
P2860
P304
P356
10.1097/YCO.0B013E328355E1AC
P577
2012-09-01T00:00:00Z